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Abstract
Background: For women of reproductive age, a population-level red blood cell (RBC) folate 
concentration below the threshold 906 nmol/L or 400 ng/mL indicates folate insufficiency and 
suboptimal neural tube defect (NTD) prevention. A corresponding population plasma/serum folate 
concentration threshold for optimal NTD prevention has not been established.
Objective: The aim of this study was to examine the association between plasma and RBC folate 
concentrations and estimated a population plasma folate insufficiency threshold (pf-IT) 
corresponding to the RBC folate insufficiency threshold (RBCf-IT) of 906 nmol/L.
Methods: We analyzed data on women of reproductive age (n = 1673) who participated in a 
population-based, randomized folic acid supplementation trial in northern China. Of these women, 
565 women with anemia and/or vitamin B-12 deficiency were ineligible for folic acid intervention 
(nonintervention group); the other 1108 received folic acid supplementation for 6 mo (intervention 
group). We developed a Bayesian linear model to estimate the pf-IT corresponding to RBCf-IT by 
time from supplementation initiation, folic acid dosage, methyltetrahydrofolate reductase 
(MTHFR) genotype, body mass index (BMI), vitamin B-12 status, or anemia status.
Results: Using plasma and RBC folate concentrations of the intervention group, the estimated 
median pf-IT was 25.5 nmol/L (95% credible interval: 24.6, 26.4). The median pf-ITs were similar 
between the baseline and postsupplementation samples (25.7 compared with 25.2 nmol/L) but 
differed moderately (±3–4 nmol/L) by MTHFR genotype and BMI. Using the full population-
based baseline sample (intervention and nonintervention), the median pf-IT was higher for women 
with vitamin B-12 deficiency (34.6 nmol/L) and marginal deficiency (29.8 nmol/L) compared with 
the sufficient group (25.6 nmol/L).
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Conclusions: The relation between RBC and plasma folate concentrations was modified by 
BMI and genotype and substantially by low plasma vitamin B-12. This suggests that the threshold 
of 25.5 nmol/L for optimal NTD prevention may be appropriate in populations with similar 
characteristics, but it should not be used in vitamin B-12 insufficient populations. This trial was 
registered at NCT00207558.
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Introduction
Low folate status is associated with increased risk of adverse health outcomes, including 
megaloblastic anemia and neural tube defect (NTD)-affected pregnancies (1, 2). Folate is 
essential for DNA synthesis, cell growth and differentiation, as well as the formation and 
maturation of red blood cells (RBCs) (3, 4). Although essential throughout life, folate is 
particularly critical during early stages of human development. Low folate status in 
pregnancy has also been associated with other adverse health outcomes, including congenital 
heart defects, oral clefts, fetal growth restriction, low birth weight, and preterm delivery (1, 
2). Evidence from clinical trials and observational studies in multiple settings has shown that 
folic acid intake in the periconceptional period reduces the occurrence of NTD-affected 
pregnancies (5–7). To prevent folate-sensitive NTDs, women of reproductive age are 
encouraged to consume folate-rich foods and 400 μg of synthetic folic acid daily (8, 9). 
Successful folic acid fortification programs have been documented in several countries, 
including Canada, Costa Rica, Chile, South Africa, and the United States, resulting in a 31–
50% reduction in the prevalence of NTD-affected pregnancies, with the percentage reduction 
dependent on folic acid dosage, intake, and baseline NTD rates (10–15).
To promote optimal NTD risk reduction at the population level, WHO recently 
recommended that the population RBC folate concentrations should be above a threshold of 
906 nmol/L (400 ng/mL) in women of reproductive age (16). In contrast, the threshold for 
preventing megaloblastic anemia is much lower (i.e., 305 nmol/L) (17). The RBC folate 
insufficiency threshold (RBCf-IT) of 906 nmol/L per WHO guidance has been used in 
countries such as the United States (18) and Guatemala (19) to evaluate the impact of 
fortification programs for the prevention of NTDs. Many countries, however, do not have 
RBC folate concentration data available; instead, they have plasma or serum folate 
concentration data for their populations because these are more widely utilized due to lower 
cost and the easier process of obtaining them. Although RBC and plasma/serum folate are 
both associated with folic acid intake (20, 21), they result from different biologic processes 
and are not interchangeable. It is generally accepted that plasma/serum folate concentrations 
reflect very recent intake, whereas RBC folate concentrations reflect both the long-term 
average of intake over the life span of RBCs and folate stores in the liver (22). Although 
ideal, currently there are no studies that link plasma/serum folate concentrations before or at 
the time of conception with NTD risk (studies in the second trimester or later are 
problematic due to hemodilution in pregnancy). Our objectives were to examine the 
association between paired plasma and RBC folate concentrations and to estimate a 
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population plasma folate insufficiency threshold (pf-IT) corresponding to the RBCf-IT of 
906 nmol/L.
Methods
Population
We used data from a population-based, double-blind randomized trial of folic acid 
supplementation conducted from 2003 to 2005 in northern China. All participants provided 
informed consent, and the project was approved by the institutional review boards at both 
the US Centers for Disease Control and Prevention and Peking University Health Sciences 
Center, Beijing, People’s Republic of China. The study design, participant eligibility, blood 
collection procedure, and methods for biochemical measurements and 
methyltetrahydrofolate reductase (MTHFR) genotyping have been previously described (23, 
24). Briefly, 1673 women of reproductive age underwent baseline assessments of 
hematologic and vitamin status (Supplemental Figure 1). Of this group, 565 women with 
anemia and/or vitamin B-12 deficiency were ineligible for folic acid intervention. The other 
1108 women were asked to take folic acid supplements for 6 mo and were randomly 
assigned to dosages of 25 μg 4 times a day, 100 μg 1 time a day, 100 μg 4 times a day, 400 
μg 1 time a day, 4000 μg 1 time a day, or 4000 μg 1 time per week. Fasting blood samples of 
RBC folate, plasma folate, vitamin B-12, homocysteine, and hemoglobin were collected at 
baseline; months 1, 3, and 6 during the supplementation trial; and month 9, which was 3 mo 
postsupplementation. Plasma and RBC folate concentrations were measured by the Molloy 
method with microbiological assays (chloramphenicol-resistant strain and folic acid 
calibrator) (25). For our purpose, we used data at baseline and 6 mo after supplementation 
(month 6), the time points when plasma and RBC folate concentrations were at or 
approaching a steady state (24). Our primary analysis used the intervention group data at 
baseline (n = 1108) and month 6 (n=977).Our secondary analysis used data from the 
intervention (n = 1108) and nonintervention (n = 565) groups at baseline. All analyses 
combined the subgroups of 25 μg 4 times a day and 100 μg 1 time a day into the 100 μg/d 
group and the subgroups of 100 μg 4 times a day and 400 μg 1 time a day into the 400 μg/d 
group because previous studies of this trial showed that the subgroups with different 
schedules but same overall doses have similar dose–response relations (24).
The primary outcomes for the original trial were to assess the changes in plasma folate, RBC 
folate, and homocysteine due to different intakes of folic acid with secondary analysis of the 
impact of MTHFR genotypes, and these have been reported previously (23, 24). The current 
analysis takes advantage of the well-characterized population-based sample of paired RBC 
folate and plasma folate concentration data to assess the association between paired plasma 
and RBC folate concentrations and to estimate a population pf-IT corresponding to the 
RBCf-IT of 906 nmol/L between different groups. The baseline sample was population-
based and included healthy, anemic, and B-12–deficient individuals. Because anemic 
individuals were excluded from receiving the folic acid intervention and were referred to 
medical care, the 6-mo postintervention sample included only nonanemic or B-12–deficient 
individuals. Groups were stratified by age, body mass index (BMI, in kg/m2), and MTHFR 
genotype.
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Statistical analysis
Descriptive analysis.—We described the data used for modeling by calculating the 
baseline characteristics for age group (<25, 25 to <35, and ≥35 years), MTHFR 677 
genotypes (CC, CT, and TT), BMI (<25, 25 to <30, and ≥30), plasma folate, RBC folate, 
plasma hemoglobin, and plasma vitamin B-12. We used the natural logarithm of plasma and 
RBC folate concentrations in all analyses to normalize the distribution of folate 
concentrations, and back-transformed to calculate the geometric mean (GM). We calculated 
and compared these characteristics for the baseline data by intervention and nonintervention 
groups using chi-square tests or nonparametric Kruskal–Wallis tests. In addition, we used 
the intervention group data at baseline and month 6 and estimated the GM and the 2.5th and 
97.5th percentiles of plasma and RBC folate concentrations overall, by folic acid dosage 
groups, MTHFR 677 genotypes (CC, CT, and TT), and BMI subgroups. We used Pearson’s 
correlation coefficient (r) to assess correlations between plasma and RBC folate 
concentrations. Similarly, we used baseline data only and calculated the GM and 2.5th and 
97.5th percentiles as well as r of plasma and RBC folate concentrations by group 
(intervention compared with nonintervention), vitamin B-12 status (deficient <148 pmol/L, 
marginal deficiency 148–221 pmol/L, and sufficient >221 nmol/L) (26), and anemia status 
(hemoglobin <120 g/L compared with ≥120 g/L).
Bayesian linear model.—We modeled RBC folate concentration as a function of plasma 
folate concentration using a linear model within the Bayesian framework. We chose the 
Bayesian framework because of the flexibility, direct inferences through the posterior 
distribution for quantities of interest, and usability of all available information. Flexibility 
allows us to model RBC folate concentration as a function of plasma folate concentration 
and obtain the posterior for the plasma distribution that corresponds to the RBC folate 
concentration threshold. We are able to use all available information for RBC folate 
concentration, plasma folate concentration, and covariates of interest in model development 
and treat missing data as additional parameters to be estimated in the modeling process. We 
investigated several models to estimate the plasma folate concentration corresponding to 
RBC folate threshold. We set 906 nmol/L as the RBC folate concentration threshold for 
optimal NTD prevention based on the WHO recommendation and previous studies (15, 27).
We used data from baseline and month 6 for the intervention group models and baseline data 
for the combined nonintervention and intervention models. We estimated intervention group 
models overall and by 1) baseline and month 6, 2) supplementation group, 3) genotype, and 
4) BMI. In addition, we estimated an overall pf-IT using a multivariable model that 
controlled for age, MTHFR genotype, and BMI. We performed sensitivity analyses to 
evaluate the impact of missing information on genotypes and BMI in the multivariable 
models, using Bayesian methods to impute missing values.
To estimate the pf-IT for the combined nonintervention and intervention groups, we 
developed Bayesian linear models (BLMs) overall and by 1) intervention and 
nonintervention group, 2) vitamin B-12 status, and 3) anemia status. We also developed an 
adjusted BLM including age, MTHFR genotypes, BMI, vitamin B-12 status, and anemia 
status as covariates.
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We used the following standard procedure for all BLMs. Our estimation procedure consisted 
of computing the joint posterior probability distribution of all parameters using a Markov 
chain Monte Carlo computational approach. We used a burn-in of 10,000 samples, drew 
500,000 samples post burn-in, and thinned by retaining every 50th sample, which resulted in 
a sample of 10,000 for our parameter estimates. We used mildly informative priors of N(0, 
10) for all parameters. In addition, for our multivariable models, we estimated the 
parameters by removing missing data and using a full Bayesian approach by treating the 
missing data as additional parameters to be estimated jointly with our model parameters of 
interest. We assumed all missing data were missing at random. In addition, for all models 
that used baseline and 6-mo data, we treated the individual as a random effect to account for 
the correlation within a person. For each model, we summarized the 10,000 posterior 
samples of the estimated pf-IT that corresponds to the RBCf-IT of 906 nmol/L. In addition, 
when appropriate, we calculated and summarized the difference of the pf-IT estimates by 
subgroup. We report the medians and 95% credible intervals (CIs) of the posterior 
distributions of the estimated pf-ITs and differences in pf-ITs. A credible interval is 
Bayesian statistics and defines a plausible range of values, within which an unobserved 
parameter value falls with a particular probability. We estimated all models using SAS 
MCMC (version 9.4; SAS Institute).
Results
Descriptive analysis
Baseline characteristics of women in the intervention and nonintervention groups are 
presented in Table 1. Women in the intervention group were more likely to be in the age 
group <25 y (P = 0.03) and had higher plasma folate, RBC folate, hemoglobin, and vitamin 
B-12 concentrations than those in the nonintervention group (P < 0.001). MTHFR 677 
genotype TT was more prevalent in the nonintervention group (43.1% compared with 
35.1%), whereas CC and CT were more prevalent in the intervention group (P= 0.04).
The GM of plasma and RBC folate concentrations did not differ substantially by dosage 
groups at baseline but differed at month 6 (Supplemental Table 1). The correlation 
coefficient (r) for plasma and RBC folate concentrations increased in the intervention group 
from 0.46 at baseline to 0.67 at month 6 (Figure 1A, Supplemental Table 1). The increase in 
r after supplementation was observed in all dosage groups except the 4000 μg/wk group 
(Figure 1C, D, E and F, Supplemental Table 1), whereas the r in the 100 μg/d group 
remained the lowest compared to other dosage groups.
Among the intervention group, women with MTHFR 677 genotype TT had lower plasma 
and RBC folate concentrations at baseline and month 6 compared with the CC and CT 
groups (Supplemental Table 1). The increase in r between plasma and RBC folate 
concentrations after supplementation was observed in all genotype groups (Figure 2A, B, 
and C, Supplemental Table 1). At baseline or month 6, the r did not differ substantially 
between genotype groups. For BMI subgroups, at baseline and month 6, the obese women 
(BMI ≥30) had higher RBC folate and lower plasma folate concentrations than 
nonoverweight/nonobese women (BMI <25) (Figure 2D, E, and F, Supplemental Table 1). 
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The r was lower in the obese women than in the nonoverweight/nonobese women and 
remained low at month 6 (Figure 2D, E, and F, Supplemental Table 1).
We found the r between plasma and RBC folate concentrations to be lower in the 
nonintervention group (0.41) compared to the intervention group (0.46) (Figure 1A, B, 
Supplemental Table 2) and also lower in the anemic group (0.35) compared with the 
nonanemic group (0.48).
Plasma threshold analysis
When using data from the intervention group, the estimated median pf-IT was 25.5 nmol/L 
(95% CI: 24.6, 26.4) (Table 2, Figure 3). Results of the subgroup analyses for the 
intervention group are summarized in Table 2 and Supplemental Figure 2. The estimated 
median pf-IT at month 6 (25.2 nmol/L) was similar to baseline (25.7 nmol/L). The estimated 
median pf-IT for the 100 μg/d group (38.4 nmol/L) was higher than that of the other three 
dosage groups, whereas those in the other three dosage groups were closer to one another 
(400 μg/d: 24.4 nmol/L; 4000 μg/d, 22.0 nmol/L; and 4000 μg/wk, 25.6 nmol/L). The higher 
estimated median pf-IT in the 100 μg/d group was observed both at baseline and at month 6 
(Supplemental Table 3). For the 4000 μg/d group, a lower estimated median pf-IT was 
observed at month 6 (13.2 nmol/L) (Supplemental Table 3); however, when removing a few 
influential observations, the 6-mo estimated median pf-IT (19.5 nmol/L) was not 
substantially different from the baseline estimated median pf-IT(22.8nmol/L).
The estimated median pf-IT was higher for the TT group (26.3 nmol/L) than the CC and CT 
groups (CC: 23.2 nmol/L; CT: 25.1 nmol/L) (Table 2, Supplemental Figure 2). The 
estimated median pf-ITs were not different by genotype groups at month 6 alone 
(Supplemental Table 3). Among BMI subgroups, the estimated median pf-IT was lowest for 
the obese group (21.9 nmol/L), followed by the overweight group (23.3 nmol/L) and the 
nonoverweight/nonobese group (26.7 nmol/L) (Table 2, Supplemental Figure 2). When 
using only baseline or 6-mo data, the estimated median pf-IT for the obese group was ~5–6 
nmol/L lower than that for the non-overweight/non-obese group (Supplemental Table 3). 
Differently, the estimated median pf-IT for the overweight group was higher at baseline but 
lower at month 6 compared to that for the nonoverweight/nonobese group. When comparing 
the unadjusted and adjusted models, we did not observe meaningful differences in all the 
threshold values (Supplemental Table 4).
Using data from all women at baseline, the estimated median pf-IT was 27.2 nmol/L (95% 
CI: 24.6, 30.9) (Table 3). The estimated median pf-IT for the intervention group was lower 
than that for the nonintervention group (25.7 nmol/L compared with 32.5 nmol/L), with a 
difference of 6.7 nmol/L (95% CI: −0.6, 18.2) (Table 3, Supplemental Figure 3). The 
estimated median pf-IT was higher for vitamin B-12–deficient and marginal deficiency 
women (34.6 and 29.8 nmol/L; respectively) compared with vitamin B-12–sufficient women 
(25.6 nmol/L) (Table 3). The difference between vitamin B-12–deficient and – sufficient 
groups was 8.9 nmol/L (95% CI: 0.4, 22.9) (Table 3, Supplemental Figure 3). The estimated 
median pf-IT was also higher for the anemic group (28.5nmol/L) than for the nonanemic 
group (26.4 nmol/L), but the difference was small (2.1 nmol/L; 95% CI: −6.3, 23.9) (Table 
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3). When comparing the unadjusted and adjusted models, we did not observe meaningful 
differences in the threshold values (Supplemental Table 5).
Discussion
We observed a moderate positive correlation of plasma and RBC folate concentrations in 
nonpregnant women of reproductive age by using data from a population-based, randomized 
trial of folic acid supplementation in northern China. In this population, 21% were vitamin 
B-12 deficient and 15% were anemic. We also generated population pf-ITs corresponding to 
RBCf-IT for optimal NTD prevention. Among nonanemic, non-vitamin B-12–deficient 
women, the estimated median pf-IT corresponding to RBCf-IT of 906 nmol/L was 25.5 
nmol/L. The estimated median pf-IT did not change after supplementation. However, the 
estimated median pf-ITs in vitamin B-12–deficient or marginal deficiency women were 
higher than with that in vitamin B-12–sufficient women. Our results suggest that the 
threshold of 25.5 nmol/L may be inappropriate for populations with high prevalence of 
vitamin B-12 deficiency or marginal deficiency.
Association between plasma and RBC folate concentrations
We found a moderate linear relation between plasma and RBC folate concentrations at 
baseline (r = 0.46 in the intervention group and r = 0.41 in the nonintervention group). The 
correlations were not substantially different by MTHFR genotype or vitamin B-12 status, 
but they were lower in obese and anemic groups. We also found the correlation increased 
after folic acid intervention (r = 0.67), implying that the individual variation of blood folate 
concentrations in the population decreased after folic acid intervention (e.g., food 
fortification). Note that the correlations are lower before intervention compared to after the 
folic acid intervention due to higher variance in the same subjects at baseline and not due to 
a difference in the slope orconclusionsconclusions intercept of the association such that there 
is more scatter around the same line (Figure 1).Another way to demonstrate that the slope of 
the association is similar between the pre- and post-intervention data is by comparing the 
median plasma folate concentration that correlates with the 906 nmol/L RBC folate 
concentration, which is almost identical [baseline, 25.7 nmol/L (95% CI: 23.0, 29.7); 6-mo 
folic acid, 25.2 nmol/L (95% CI: 23.9, 26.5); Table 2], just with wider credible intervals at 
baseline that reflect the higher variance in the baseline data. It is not surprising to have less 
variance in crude r2 correlation at low concentrations when a small absolute change 
produces a larger percentage change and that variance decreases when the population is 
homogenized by 6 mo of folic acid supplementation and much higher concentrations, where 
the same absolute difference is a much smaller percentage change. Previous Irish studies 
with blood folate samples collected among pregnant women who attended the antenatal 
clinic showed the correlation coefficient of RBC and plasma folate to be 0.61–0.71 (28), 
which is consistent with the postsupplementation data. However, it is difficult to compare 
the reported correlation coefficients with our estimates due to difference in pregnancy status 
and lack of information on folic acid supplementation, baseline folate concentrations, and 
genetic or biologic characteristics.
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Population plasma folate concentration insufficiency threshold
In our study, for nonanemic, non-vitamin B-12–deficient women, the estimated median pf-
IT corresponding to RBCf-IT of 906 nmol/L for optimal NTD prevention (< 8 NTD per 
10,000 births) was 25.5 nmol/L. A previous nested case–control study of women in the 
second trimester found that the subpopulation with plasma folate concentration >15.9 
nmol/L was associated with a lower risk of NTDs (< 9 per 10,000 births) (29). Due to 
hemodilution of pregnancy, which leads to lower plasma/serum folate concentration in 
normal pregnancy (30), it may be inappropriate to compare this plasma concentration with 
the one derived from nonpregnant women in our study. The difference in plasma folate 
concentration thresholds might also be influenced by the limited number of participants in 
the previous study and by biological factors such as race/ethnicity or environmental factors 
such as different food sources between the two different populations.
Effect of folic acid supplementation.—This analysis finds that folate metabolism and 
possibly transportation into the cell change the plasma folate equivalent of the 906 nmol/L 
threshold (B-12, MTHFR, and BMI), whereas 6 mo of folic acid supplement in and of itself 
does not change the pf-IT (such that those whose RBC folate concentration is 906 nmol/L 
have similar plasma folate concentrations at baseline as those who have consumed folic acid 
supplements and have RBC folate concentrations of 906 nmol/L). When stratifying by folic 
acid dosage groups, the pf-IT for the 100 μg/d group was higher than those of the other three 
dose groups. However, the additional analysis on the 100 μg/d group revealed that the pf-ITs 
did not differ by baseline and 6 mo of supplementation, suggesting that factors other than 
supplementation affect the relation between plasma and RBC folate concentrations in this 
subgroup. Given that the women in the original trial were randomly allocated to each dose 
group and there was no difference in baseline characteristics between dose groups (24), it 
might be an unmeasured confounder that results in the difference in plasma threshold 
estimates for the 100 μg/d group. Because our model was intended to reflect true population 
variance of plasma and RBC folate concentrations, we retained the 100 μg/d group data in 
the final overall model.
Effect of MTHFR genotype.—The MTHFR genotype variation (667C>T transition) is a 
determinant of folate status in women of reproductive age (31). Studies have shown that the 
genetic variant TT was associated with lower plasma/serum and RBC folate concentrations 
(23) and increased risk of NTDs (32). Previous modeling showed that MTHFR genotype 
variation does not modify the relation of RBC folate concentration threshold and NTD risk 
in the population (33), although additional folate intake would be needed for a population 
with the MTHFR T alleles to achieve a specific RBC folate concentration. Genotype TT, 
which links to lower concentrations of RBC and plasma folate concentrations, had a higher 
pf-IT than CC and CT groups (trend TT > CT > CC). When further stratifying data of 
genotype subgroups by different time points, the trend of the pf-ITs among genotype 
subgroups was found at baseline but not after 6 mo of folic acid supplementation. Our 
findings suggest that the differences between RBC folate and plasma folate concentrations 
due to genotype are moderated after folic acid supplementation.
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Effect of BMI.—Our study revealed an inverse trend between BMI and pf-IT: higher BMI 
is associated with a lower plasma threshold. This association is consistent with results from 
previous studies among US women showing that higher BMI was associated with lower 
serum folate but higher RBC folate concentrations (34, 35). A possible explanation for this 
observation could be that the altered distribution of folate as body size increases leads to a 
change in the body pool of freely available plasma/serum folate and folate in the cell (36, 
37). Obesity is also thought to affect folate metabolism (e.g., higher cellular uptake of the 
developing erythrocytes) (38), but the effect has not yet been determined. In addition, a US 
study (35) found that the use of folic acid supplements modified the inverse association 
between serum folate concentration and BMI: lower serum folate concentrations were 
associated with higher BMI among supplement nonusers but not among users. However, in 
our study, the inverse association between BMI and pf-IT remained after 6 mo of 
supplementation. Further studies are needed to delineate the associations between BMI, folic 
acid intake, and the two different folate status indicators (plasma and RBC folate).
Effect of vitamin B-12.—We found that lower vitamin B-12 status is associated with 
much higher pf-IT. Vitamin B-12 is directly involved in folate metabolism and required for 
folate retention in developing RBC, thus leading to functional folate deficiency and impaired 
erythropoiesis (1). Vitamin B-12 serves as a coenzyme in methionine synthase reaction [i.e., 
the conversion of 5-methyl-tetrahydrofolate (5-methyl-THF) to THF]. Vitamin B12 
deficiency can lead to reduced methionine synthase reaction, causing 5-methyl-THF to 
accumulate in the “methyl trap” (39). The effect of vitamin B-12 status on the relation 
between RBC folate and plasma folate highlights the differences between the two folate 
biomarkers and suggests caution in using a pf-IT in the context of lower vitamin B-12 
intakes. Vitamin B-12 deficiency should be corrected because there are clinical 
consequences beyond those associated with folate deficiency (e.g., neurological damage). In 
populations with a high prevalence of vitamin B-12 deficiency and insufficiency, correction 
of both vitamin B-12 deficiency and low folate status could be considered and RBC folate, 
plasma/serum folate, and vitamin B-12 monitored.
Strengths and limitations
This study has several strengths. This was a large population-based study with multiple 
biomarkers available for each subject. There was high compliance with folic acid 
supplementation, allowing us to show the correlations and pf-IT estimates between different 
subgroups receiving different dosages. Furthermore, MTHFR genotype information was 
available, allowing us to examine if genotype affects plasma folate concentration thresholds.
One study limitation is that we used folic acid concentration measured after 6 mo of 
supplementation in the analysis. This assumes that blood folate, particularly RBC folate, has 
reached a steady state. Studies have shown that it takes ~6–12 mo for RBC to reach a steady 
state, whereas it takes less time for plasma/serum to do so (40–44). The timing to reach a 
steady state also depends on the dosage of folic acid supplementation (43–45). RBC folate 
concentrations in women who take high doses (e.g., >1 mg/d) may plateau earlier than those 
in lower dose groups. Our previous study, which used the same China data, showed that the 
plasma concentration plateaued at 3 mo but RBC concentration had not plateaued by 6 mo 
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(24). Because in the trial folic acid supplementation was withdrawn after 6 mo, we could not 
determine whether the RBC folate concentration increased after this period or whether it 
reached a plateau between 3 and 6 mo. However, an assumption of steady state may not be 
so important because we found no substantial difference in the pf-ITs between baseline and 
after 6 mo of supplementation.
This study is also limited in that this correlation is limited to the microbiological assay and 
is not generalizable to other assays. In addition, the folate measurements in this study were 
taken under fasting conditions, which limited our ability to assess the effect of fasting. Last, 
this study only included women of reproductive age in northern China, with a background of 
high (35.1%) prevalence of TT genotype (23). More studies using data from other 
populations in different settings will help determine if our findings of the association 
between plasma and RBC folate concentrations and the pf-ITs can be applied to other 
populations.
Implications
RBC and plasma folate concentrations, although highly correlated, are not identical 
biomarkers of folate status, and their relation is affected by BMI, MTHFR genotype, and 
especially vitamin B-12 status. Previous studies in various populations have consistently 
shown that as RBC folate concentration increases, NTD risk decreases; for example, a 4-fold 
increase in RBC concentration, from 300 nmol/L to 1200 nmol/L, was associated with up to 
a 10-fold decreased risk of NTDs (33). WHO has established that the RBC folate 
insufficiency threshold for optimal NTD prevention is 906 nmol/L, and this threshold 
(adjusted for folate assay method) helped Guatemala evaluate its fortification program. 
Fortification was found to be relatively effective at increasing blood folates in urban areas 
(~19% of the population under the RBCf-IT) but was not effective in reaching rural and 
indigenous populations (~ 81% under the RBCf-IT in Norte region) (19). The pf-IT could be 
used by programs to determine what percentage of their population is likely to be folate 
insufficient for optimal NTD prevention. High rates of plasma folate insufficiency would 
indicate a need to implement an appropriate folic acid fortification or supplementation 
program. Although RBC folate concentration distributions are still needed to predict NTD 
prevalence, use of a population plasma folate insufficiency threshold could help programs 
with existing plasma folate data plan and initiate fortification programs.
Conclusions
We estimated that the population-based median pf-IT corresponding to RBCf-IT of 906 
nmol/L is ~25.5 nmol/L. We observed no substantial change in estimated median pf-IT after 
folic acid supplementation, and only moderate changes by MTHFR genotype and BMI. The 
estimated median pf-IT among vitamin B-12–deficient women was much higher than that of 
vitamin B-12–sufficient women, suggesting the threshold may be inappropriate for 
populations with vitamin B-12 insufficiency or other characteristics different from those of 
our study population.
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FIGURE 1. 
Correlation plots between plasma and RBC concentrations at baseline (month 0) and after 6 
mo of supplementation. Plots show the natural log-transformed plasma and RBC folate 
concentrations for (A) the intervention group (baseline n = 1108, 6 mo n = 977), (B) the 
non-intervention group (n = 565), and different folic acid dosage groups (C: baseline n = 
368, 6 mo n = 330; D: baseline n = 371, 6 mo n = 332; E: baseline n = 183, 6 mo n = 162; F: 
baseline n = 186, 6 mo n = 153). The values of correlation coefficients (r) are shown in each 
panel. RBC, red blood cell
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FIGURE 2. 
Correlation plots between plasma and RBC concentrations at baseline (month 0) and after 6 
mo of supplementation. Plots show the natural log-transformed plasma and RBC folate 
concentrations for MTHFR 677 genotype groups (A: baseline n = 163, 6 mo n = 159; B: 
baseline n = 448, 6 mo = 434; C: baseline n = 330, 6 mo n = 361) and BMI groups (D: 
baseline n = 670, 6 mo n = 584; E: baseline n = 287, 6 mo n = 260; F: baseline n = 69, 6 mo 
n = 60). Data included only women who received the folic acid intervention. The estimated 
correlation coefficients (r) are shown in each panel. RBC, red blood cell.
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FIGURE 3. 
Estimated plasma folate concentration corresponding to the RBC folate concentration of 906 
nmol/L using data from the intervention group (includes baseline and 6 mo). The dashed line 
represents the median, and the values of the estimated median and 95% credible interval are 
shown. CI, Bayesian credible interval; RBC, red blood cell.
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TABLE 2
Estimated plasma folate concentrations corresponding to the red blood cell folate concentration of 906 nmol/L 
using data from the intervention group, stratified by subgroups1
Median plasma folate
concentration in
nmol/L (95% CI)
Median difference
(95% CI)
Overall 25.5 (24.6, 26.4) —
Time
 Baseline 25.7 (23.0, 29.7) Reference
 Month 6 25.2 (23.9, 26.5) −0.5 (−4.7, 2.6)
Folic acid dosage
 100 μg/d 38.4 (33.3, 45.8) 13.9 (8.7, 21.5)
 400 μg/d 24.4 (23.1, 25.9) Reference
 4000 μg/d 22.0 (20.5, 23.6) ‒2.4 (‒4.4, ‒0.4)
 4000 μg/wk 25.6 (23.0, 28.8) 1.0 (‒1.8, 4.5)
MTHFR 677 genotype
 CC 23.2 (21.2, 25.5) Reference
 CT 25.1 (23.8, 26.6) 1.9 (−0.7, 4.4)
 TT 26.3 (24.6, 28.2) 3.1 (0.2, 5.9)
BMI, kg/m2
 <25 26.7 (25.5, 28.1) Reference
 25 to <30 23.3 (21.9, 25.0) −3.3 (−5.3, −1.4)
 ≥30 21.9 (19.0, 26.1) −4.5 (−8.0, −0.5)
1
Includes data from the intervention group at baseline and 6 mo (n = 2085). CI, Bayesian credible interval; MTHFR, methylenetetrahydrofolate 
reductase.
Am J Clin Nutr. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chen et al. Page 20
TABLE 3
Estimated plasma folate concentrations corresponding to the red blood cell folate concentration of 906 nmol/L 
using data from all women at baseline, stratified by subgroups1
Median plasma folate
concentration in
nmol/L (95% CI)
Median difference
(95% CI)
Overall 27.2 (24.6, 30.9) —
Subgroup
 Intervention 25.7 (23.0, 29.7) Reference
 Non-intervention 32.5 (26.4, 43.6) 6.7 (−0.6, 18.2)
Vitamin B-12, pmol/L
 <148 34.6 (27.6, 48.2) 8.9 (0.4, 22.9)
 148–221 29.8 (24.1, 40.8) 4.2 (−3.4, 15.5)
 >221 25.6 (22.3, 30.7) Reference
Hemoglobin, g/L
 120 28.5 (20.9, 50.1) 2.1 (−6.3, 23.9)
 ≥120 26.4 (23.8, 29.8) Reference
1
Includes data from the intervention and the non-intervention groups at baseline (n = 1673). CI, Bayesian credible interval.
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